Karen Hatten
Family · Oglethorpe, GANPI 1396704995
Payments from drug & device makers
Across 144 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$770
- AstraZeneca$369
- Novo Nordisk$357
- Boehringer Ingelheim$243
- Lilly USA, LLC$236
- Novartis$118
- plus $357 from 9 others
What the payments were for
- Food & beverage$2,450100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 43 | $770 |
| AstraZeneca | 25 | $369 |
| Novo Nordisk | 21 | $357 |
| Boehringer Ingelheim | 13 | $243 |
| Lilly USA, LLC | 14 | $236 |
| Novartis | 7 | $118 |
| Sanofi-aventis U.S. LLC | 4 | $62 |
| Esperion Therapeutics, Inc. | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Exact Sciences | 3 | $56 |
| Amgen | 2 | $31 |
| Merck | 2 | $30 |
| AbbVie | 1 | $24 |
| Dexcom, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$2,450 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 182 | $229,129 |
| OzempicSemaglutide | 54 | $61,957 |
| TrulicityDulaglutide | 41 | $59,981 |
| TradjentaLinagliptin | 44 | $47,354 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $44,891 |
| JardianceEmpagliflozin | 50 | $44,476 |
| ProliaDenosumab | 20 | $34,874 |
| LinzessLinaclotide | 33 | $31,917 |
| FarxigaDapagliflozin Propanediol | 31 | $30,841 |
| RybelsusSemaglutide | 12 | $27,306 |
| JanuviaSitagliptin Phosphate | 16 | $25,645 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $25,024 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $23,081 |
| CreonLipase/Protease/Amylase | 12 | $22,188 |
| MyrbetriqMirabegron | 26 | $21,459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $236 | $289,110223 claims |
| Boehringer IngelheimTradjenta, Jardiance, Glyxambi | $243 | $108,862108 claims |
| Novo NordiskOzempic, Rybelsus | $357 | $89,26366 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $770 | $67,97275 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $369 | $64,58980 claims |
| AbbVieLinzess, Creon | $24 | $54,10545 claims |
| AmgenProlia | $31 | $34,87420 claims |
| MerckJanuvia | $30 | $25,64516 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $62 | $14,52712 claims |
| NovartisEntresto | $118 | $7,27111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Oglethorpe
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.